A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma

PM Voorhees; RF Manges; Pieter Sonneveld; S Jagannath; G Somlo; A Krishnan; S Lentzsch; RC Frank; S Zweegman; PW Wijermans; RZ Orlowski; B Kranenburg; B Hall; T Casneuf; X Qin; H te Velde; H Xie; SK Thomas

doi:10.1111/bjh.12266

A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma

PM Voorhees, RF Manges, Pieter Sonneveld, S Jagannath, G Somlo, A Krishnan, S Lentzsch, RC Frank, S Zweegman, PW Wijermans, RZ Orlowski, B Kranenburg, B Hall, T Casneuf, X Qin, H te Velde, H Xie, SK Thomas

Hematology

Research output: Contribution to journal › Article › Academic › peer-review

137 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	357-366
Number of pages	10
Journal	British Journal of Haematology
Volume	161
Issue number	3
DOIs	https://doi.org/10.1111/bjh.12266
Publication status	Published - 2013

Research programs

EMC MM-02-41-03

Access to Document

10.1111/bjh.12266

Cite this

Voorhees, PM., Manges, RF., Sonneveld, P., Jagannath, S., Somlo, G., Krishnan, A., Lentzsch, S., Frank, RC., Zweegman, S., Wijermans, PW., Orlowski, RZ., Kranenburg, B., Hall, B., Casneuf, T., Qin, X., te Velde, H., Xie, H., & Thomas, SK. (2013). A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. British Journal of Haematology, 161(3), 357-366. https://doi.org/10.1111/bjh.12266

@article{0520724d84ac4d5c8ab727c36ead6b9c,

title = "A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma",

author = "PM Voorhees and RF Manges and Pieter Sonneveld and S Jagannath and G Somlo and A Krishnan and S Lentzsch and RC Frank and S Zweegman and PW Wijermans and RZ Orlowski and B Kranenburg and B Hall and T Casneuf and X Qin and {te Velde}, H and H Xie and SK Thomas",

year = "2013",

doi = "10.1111/bjh.12266",

language = "Undefined/Unknown",

volume = "161",

pages = "357--366",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley & Sons Inc.",

number = "3",

}

Voorhees, PM, Manges, RF, Sonneveld, P, Jagannath, S, Somlo, G, Krishnan, A, Lentzsch, S, Frank, RC, Zweegman, S, Wijermans, PW, Orlowski, RZ, Kranenburg, B, Hall, B, Casneuf, T, Qin, X, te Velde, H, Xie, H & Thomas, SK 2013, 'A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma', British Journal of Haematology, vol. 161, no. 3, pp. 357-366. https://doi.org/10.1111/bjh.12266

TY - JOUR

T1 - A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma

AU - Voorhees, PM

AU - Manges, RF

AU - Sonneveld, Pieter

AU - Jagannath, S

AU - Somlo, G

AU - Krishnan, A

AU - Lentzsch, S

AU - Frank, RC

AU - Zweegman, S

AU - Wijermans, PW

AU - Orlowski, RZ

AU - Kranenburg, B

AU - Hall, B

AU - Casneuf, T

AU - Qin, X

AU - te Velde, H

AU - Xie, H

AU - Thomas, SK

PY - 2013

Y1 - 2013

U2 - 10.1111/bjh.12266

DO - 10.1111/bjh.12266

M3 - Article

C2 - 23432640

SN - 0007-1048

VL - 161

SP - 357

EP - 366

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 3

ER -